Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group Plc LSE:DEMG London Ordinary Share GB0059337583 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1.325 1.25 1.40 1.325 1.325 1.33 298,387 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 4.3 -0.2 -0.0 - 7

Deltex Medical Share Discussion Threads

Showing 21276 to 21298 of 21625 messages
Chat Pages: Latest  853  852  851  850  849  848  847  846  845  844  843  842  Older
DateSubjectAuthorDiscuss
28/4/2020
10:15
Couldn't agree more, it's prohibiting volume rather than encouraging it.
tickboo
28/4/2020
10:15
Yeh I had same issue in Tils yesterday, some good news took it up 20% but on paper it was only 5%. Lots of risk and poor reward. Amgo was the same.
slinkyj
28/4/2020
10:14
I heard on the SNG board too and hold 27,500 there.Sold a fair number in NCYT and did very well and not have 60,000 in AVCT which is looking great and should bank some profit but think they'll make the pregnancy style test work and that'll be a game changer. If it doesn't work it'll obviously get smashed! Depending on selling other shares I'd like to get another 500k or 1m to make 1.5m here as see great value and now they're generating cash and surely demand on the up it'll go higher and higher.
tickboo
28/4/2020
10:13
Nice Nobby, well I'm about 1/8 of that lol. Would be nice double up here now.
slinkyj
28/4/2020
10:06
I hold over 4 million so yes still here. Bought another 200k this morning.
nobbygnome
28/4/2020
10:05
Good good, I got in earlier with a punt thanks to his whisper in SNG board. Still in SNG, but sliced some profits from hemo earlier and wanted to put it to some good
slinkyj
28/4/2020
09:41
I hold 500,000 here which was put on my radar by Nobby so I'm pretty sure he does hold and thanks for the tip/heads up to me and others. I think the spread is ridiculous and although will be tighter in reality (dummy buys) they really need to sort it out.
tickboo
28/4/2020
09:36
DEMG for some strange reason doesn't seem to trade with large investors until around 1045-1100 hrs so expecting a few lumpy trades in the next few hours imho!
gbenson1
28/4/2020
09:21
You still invested here Nobby?
slinkyj
28/4/2020
09:20
Nearly 1m buys so farThink you might be right in which case we might dare to hope for a decent tick up before a lovely leisurely lockdown lunchMrC
mrc2u
28/4/2020
08:02
Still the more appropriate thread title for this shareThe LID gap remains high
trentendboy
28/4/2020
06:50
Given the very positive TP broker note I expect plenty of buy volume today as investors/institutions wake up to DEMGs potential. The large buy order I mentioned yesterday I feel is still being worked by the mms so the bid/sell price will be held high so mms can obtain stock, imho!
gbenson1
28/4/2020
06:33
Thanks Nobby. G.
garth
28/4/2020
06:21
Yes an awfully long time; the header was written in 2011. All the way up to 30p and back. However, I bough £60k of shares in the fund raising 2 years ago at 1.25p and have traded the shares profitability frequently so break even for me is now at about 1.5p. A take out at around 4-5p would go down very well with me.
nobbygnome
28/4/2020
06:19
Nobby, you have been in these a long time. When was the header text written? - I took a stake following the results but want to get a better feel before increasing. Thanks, G.
garth
28/4/2020
06:18
No worries and unfortunately given the necessary demand given the global crisis I imagine the more they're used given it's an incestuous filed word will get around more and more. I can only see, as suggested demand will continue to rise and surely Deltex will be getting on some radars with deep pockets.
tickboo
28/4/2020
06:09
And buywell did you see the TP note suggesting DEMG were ripe for a takeover because of their novel technology? Nothing about that fro poor old LID. it is becoming increasingly clear that DEMG is the strong buy and LID are ridiculously overvalued. Buy the former and sell the latter is the obvious conclusion, although no investment advice intended!
nobbygnome
28/4/2020
05:15
Cheers for the note, very interesting and whilst we were probably on a long term, steady recovery, this is now a game changer.....fascinated to see the takeover likelihood rise as well....
chrisdgb
28/4/2020
04:26
Thanks for the Turner Pope broker note, very interesting, I found it had more detail than the RNS but I guess the company can't speculate or offer potential outcomes. I particularly liked the "may" be susceptible to a predator/takeover?
gbenson1
28/4/2020
03:48
buywell is slowly bringing you guys to the light it seems so a little treat. On Covid-19 topic , buywell thought you guys would like this : According to the Ultraviolet Germicidal Irradiation Handbook, one minute of UV-C light sterilizes more than 90% of [other versions of] the coronavirus. Tests conducted by Chinese agencies on appliances equipped with violeds UV LED sterilization have demonstrated a 97% reduction in airborne virus particles. hTtps://www.youtube.com/watch?v=pJo1p-RDKc4 Cleaning of PPE and equipment by UVC now also taking place The device, called HealthySole® PLUS, is being introduced in hospitals and other settings where infection control is urgent. hTtps://www.techgenyz.com/2020/04/27/healthysole-deactivates-human-coronavirus-on-footwear/ A recent Center for Disease Control (CDC) report points out that the virus is spread through floors and foot traffic, and not just by person-to-person contact. UVC cleaning Hospitals htTps://www.eastmojo.com/coronavirus-updates/2020/04/25/uv-disinfection-trolley-to-disinfect-99-of-virus-in-hospitals buywell thinks China looks light years ahead of the UK In the USA they don't use manpower hTtp://emag.directindustry.com/disinfection-robots-against-covid-19/ A thought from buywell If you believe that SARS-COV-2 will be around for some time , or you believe that there will be a SARS-COV-3/4/5 etc coming along There is likely thinks buywell to be a rapid expansion of UVC infection control of public areas eg hTtps://www.thelocal.de/20200426/german-start-up-in-global-demand-with-anti-virus-escalators You can see UVC disinfecting being applied not only in Hospitals , but in schools and colleges , banks and offices , government offices/buildings , public transport , including buses trains and planes , anywhere where there is a down time eg night to do the UVC infection cleaning . Plus most likely a home unit A growth market pointed out by buywell IMO dyor
buywell3
27/4/2020
16:36
Indeed, I took note of this too -Deltex Medical's business outlook appears to have improved quite dramatically in just the past few months, to the extent that much larger sector players envious of the Group's preeminent Doppler monitoring research and development know-how and IP may already be considering their opportunities to gain control.
tickboo
27/4/2020
15:49
So they are speculating on a takeover....must be true then. I am ploughing in tomorrow morning.....😜;
nobbygnome
27/4/2020
15:38
TP note -Living up to the market's best expectations, Deltex Medical delivered a pre-exceptional operating profit for its year to December 2019, while also ending the period with a reasonable cash cushion. The benefits of restructuring undertaken over the past 18 months, combined with a new strategy focussed on cost elimination and raised efficiencies, now place the Group on a springboard for grow both through the current situation and the post-Pandemic period. In this respect, it is significant that UK and US intensive care units have already started placing orders for its specialist haemodynamic monitoring technology, with a view to assisting clinicians select the optimal treatment regime for ventilated COVID-19 patients. With potential for such equipment to become standardised and made widely available across global health authorities going forward, as governments commit significant new, long-term funding in an attempt to ensure they can much more rapidly address any such future calamity, Deltex Medical appears to be ideally placed to capitalise on such opportunities while also potentially contributing to a safer living environment for international populations.Amid the COVID-19 Pandemic to date, the investment community has primarily focussed on the international populations' immediate needs – specifically that of detection, diagnostics and vaccination – for which it has awarded a significant premium to the wider healthcare development sector in the process. Yet, most are now recognising that eradication of the virus itself is probably only one-third of the true challenge that now faces the global community. The other two-thirds will likely be found firstly in a significant redirection of government healthcare funding to more realistically face up to and cope with human vulnerabilities and, only then, to refocus on picking up the present 'car crash' of the developed-world economies in order to return to past agendas of growth, advancement and security. A number of companies, like Deltex Medical, appear capable and potentially ideally placed to offer their unique technologies, facilities and know-how to a post- Pandemic environment, that is likely to have become populated by newly hungry and well-funded public and private healthcare systems/organisations urgently seeking such solutions.For its year-ended 31st December 2019, Deltex Medical posted an operating profit (excluding exceptional items) of £90,000 (2018: loss £943,000), leading to a positive adjusted EBITDA of £0.4 million (2018: loss £0.7 million). Revenues £4.3 million (2018: £5.0 million), reflected a focus on profitable business, lower sales & marketing spend and cessation of a third-party distribution agreement, allowing overheads (before exceptional costs) to decrease by £1.3 million to £3.2 million (2018: £4.5 million). Sales & marketing spend decreased by 44% to £1.2 million (2018: £2.2 million), reflecting significantly smaller teams in the USA and UK due to the initiatives taken during the period. Cash/cash equivalents at period-end was £0.9 million (2018: £0.6 million).Since the year end, refocussing by international healthcare operators in order to cope with the unprecedented demand created by the COVID-19 infection has, not surprisingly, reduced demand for the Group's Doppler probes from operating rooms. Such deferrals of elective surgery, however, are likely to be only be temporary and something of a 'rush' might be anticipated during 2H 2020, in anticipation of a forthcoming general containment of the Pandemic. The step-demand increase for its TrueVue Doppler systems in intensive care units ('ICU') that has been seen both from the UK & USA during Q1 2120 due to the Pandemic, however, is expected to be sustained. TPI considers together these will likely be sufficient to enable the Group to further raise reported revenues in the current year, while also generating good improvements in net profits and EPS.Deltex Medical rightly claims global leadership in oesophageal Doppler monitoring. Uniquely, its twenty-two randomised controlled trials demonstrate the benefit of measuring aortic blood flow (using TrueVue Doppler) to optimise the clinical management of patients. In such a setting, these represent an extremely valuable asset for the Group, effectively allowing it to set the MedTech industry's technological standards and points of reference for such equipment, a significant feature that cannot be claimed by any of its peer group. This point is highly relevant now that the world's eyes are on the very real threat of coronavirus and similar respiratory pandemics to the human race's wellbeing. As such, Deltex Medical's business outlook appears to have improved quite dramatically in just the past few months, to the extent that much larger sector players envious of the Group's preeminent Doppler monitoring research and development know-how and IP may already be considering their opportunities to gain control.
tickboo
Chat Pages: Latest  853  852  851  850  849  848  847  846  845  844  843  842  Older
ADVFN Advertorial
Your Recent History
LSE
DEMG
Deltex Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201130 14:35:24